Guwahati: The emergency use authorization for Covaxin for the age group of 6-12 years has been approved by the Drugs Controller General of India (DGCI).
The Drug Controller General of India (DGCI) has directed Bharat Biotech, the Hyderabad based pharmaceutical company, to submit safety data including the data on adverse events with proper analysis within a span of 15 days for the first two months.
According to reports, the DGCI will most likely permit the emergency use authorization of Corbevax COVID-19 vaccines for children aged between 5-12 years.
Earlier on April 21, the restricted emergency use of Biological E's Corbevax COVID-19 vaccine was recommended by the DCGI's Subject Expert Committee (SEC) for children aged 5-12 years.
As per reports, the subject expert committee has asked for additional data from Bharat Biotech for Covaxin below 12 years.
Biological E's Corbevax COVID-19 vaccine is currently being administered to children in the age group of 12-14 years.
Meanwhile, COVID-19 vaccinations for minors in India commenced from January 3 onwards. The vaccination drive started for the age group of 15-18 years and anyone falling under this category was eligible to take Bharat Biotech's Covaxin.
The vaccine drive later expanded on March 16 to include children aged above 12 for Corbevax. Altogether, two COVID-19 vaccines are currently being administered by India for children above 12 years of age.
Meanwhile, Union Health Minister Mansukh Mandaviya took to his official Twitter handle to inform about the DGCI's approval of Covaxin for the 6-12 age group and Corbevax for 5-12 age group.